AI Consensus Investment Thesis
Medtronic (MDT) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$102
+10.6%+13.1% incl. dividends5-Year
BUY$145
+56.9%+75.8% incl. dividendsLatest flagship insight
Accelerating Clinical Moats Drive Cash Compounding Beyond Bureaucratic Stagnation
High consensus confirms underlying organic growth has inflected toward 7%, driven by pulsed field ablation dominance and non-cyclical demographic demand. Valuation re-rating faces sharp divergence, as 5% Treasury yields, hospital capital rationing, and electrophysiology price wars cap multiple expansion.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Michael Burry (Vulture), Elon Musk (Visionary), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist), J.P. Morgan (Titan), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Medtronic at the forecast anchor (2026-09-18): $17,580 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 2.3% net dividend yield for Medtronic.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 94.40 | +2.47% | +2.47% | The MiniMed split-off exchange offer concludes, retiring roughly 4% of parent shares. Sustained double-digit electrophysiology volume growth counters elevated Treasury yields, allowing per-share cash accretion to produce a measured initial valuation advance. |
| Q1 2027 | 97.01 | +2.76% | +5.30% | Third-quarter results demonstrate underlying organic demand holding near 7% after stripping out calendar distortions. Expanding commercial coverage for renal denervation procedures and steady cardiac pacing replacements reinforce confidence, prompting steady institutional accumulation. |
| Q2 2027 | 99.50 | +2.56% | +7.99% | Fiscal 2027 closes with solid earnings, but forward fiscal 2028 guidance reveals optical revenue contraction from diabetes deconsolidation. Resilient consumable cash flows prevent severe drawdowns, though headline-driven allocator caution temporarily caps quarterly performance. |
| Q3 2027 | 101.87 | +2.39% | +10.58% | Initial post-split reporting clarifies underlying operating margin expansion and higher revenue quality. Sustained international Affera catheter pull-through dispels deceleration fears, prompting sell-side margin upgrades and renewed upward valuation momentum. |
| Q4 2027 | 104.84 | +2.91% | +13.80% | Manufacturing efficiency gains and cleanroom automation begin lowering unit production costs across cardiovascular product lines. High-margin disposable catheter utilization accelerates, translating volume growth into positive operating leverage and steady equity gains. |
| Q1 2028 | 106.54 | +1.62% | +15.64% | Hospital capital budget tightening and seasonal respiratory pressures temporarily moderate large-scale equipment installations. However, non-deferrable chronic implant procedures cushion cash flow, keeping equity pricing resilient despite selective competitive discounting in electrophysiology. |
| Q2 2028 | 110.05 | +3.30% | +19.45% | Full-year fiscal 2028 earnings validate structural operating margins exceeding 18.5%. Cash generation comfortably funds the 51st consecutive annual dividend increase, attracting defensive institutional capital seeking dependable yields amid late-cycle macroeconomic deceleration. |
| Q3 2028 | 112.20 | +1.95% | +21.78% | Spine navigation integration and cranial technology suites drive steady surgical implant cross-selling. Incremental procedural adoption offsets Section 301 component tariff friction, supporting stable earnings visibility and moderate share price compounding. |
| Q4 2028 | 115.11 | +2.59% | +24.94% | Outpatient renal denervation adoption broadens across commercial payers, scaling cath-lab procedure volumes. Favorable therapeutic mix and maturing manufacturing lines lift free cash flow conversion, reinforcing market perception of genuine operational turnaround. |
| Q1 2029 | 117.25 | +1.87% | +27.27% | Rival medtech entries in pulsed field ablation trigger competitive pricing friction across European accounts. Procedure volumes continue expanding, but narrower catheter average selling prices moderate incremental operating leverage, leading to modest consolidation. |
| Q2 2029 | 119.86 | +2.22% | +30.09% | Fiscal 2029 results highlight robust trailing free cash flow exceeding $6.8 billion. Operating expense discipline successfully absorbs international volume-based procurement cuts, enabling opportunistic anti-dilutive share repurchases that support per-share intrinsic value. |
| Q3 2029 | 122.05 | +1.83% | +32.47% | Scheduled manufacturing facility consolidations and plant rationalizations generate permanent structural cost savings. Non-cyclical demographic demand for structural heart implants buffers broader economic weakness, ensuring dependable defensive financial performance. |
| Q4 2029 | 125.43 | +2.77% | +36.15% | Second-generation pulsed field ablation catheters and navigation software integrations launch globally. Enhanced clinician retention and recurring consumable reorders re-accelerate cardiovascular margins, driving positive institutional sentiment and solid quarterly appreciation. |
| Q1 2030 | 127.62 | +1.74% | +38.52% | Higher-for-longer sovereign interest rates continue capping valuation multiple expansion across large-cap medtech. Nevertheless, disciplined working capital management and steady neurostimulation replacement cycles ensure resilient cash compounding without balance-sheet strain. |
| Q2 2030 | 130.76 | +2.47% | +41.93% | Fiscal 2030 financial disclosures demonstrate adjusted operating margins approaching 20% on the optimized post-separation portfolio. Strong free cash flow conversion reinforces dividend aristocrat positioning, underpinning durable mid-single-digit shareholder returns. |
| Q3 2030 | 133.19 | +1.86% | +44.57% | Seasonal summer surgical moderation slightly tempers quarterly revenue velocity. Established enterprise hospital bundling contracts and steady cardiac pacing implants protect baseline operating profits, preserving recent valuation gains. |
| Q4 2030 | 136.39 | +2.40% | +48.04% | Matured renal denervation and robotic surgical instrumentation cohorts deliver consistent, high-margin consumable annuities. Broadening international procedures cushion domestic pricing scrutiny, sustaining steady per-share cash flow expansion and upward price tracking. |
| Q1 2031 | 138.53 | +1.57% | +50.37% | Pricing pressures in standardized vascular commodities are fully mitigated by high-volume transcatheter aortic valve deployments. Investors value the franchise as an essential healthcare compounder, supporting share prices through steady operational execution. |
| Q2 2031 | 141.94 | +2.46% | +54.06% | Fiscal 2031 results mark the completion of a five-year turnaround, with annual free cash flow approaching $7.5 billion. Expanding owner earnings and disciplined balance sheet deleveraging validate the long-term margin recovery thesis. |
| Q3 2031 | 144.56 | +1.85% | +56.91% | The forecast horizon closes with valuation anchored by durable cash compounding and disciplined share count reduction. Structural procedure growth across an aging global population secures steady terminal cash generation. |
Medtronic's core investment thesis represents an operational transition from conglomerate stagnation to high-margin cash compounding. Underlying organic top-line velocity has inflected to approximately 7%, once adjusted for the 53-week fiscal distortion, propelled by rapid adoption of Affera Sphere-9 pulsed field ablation, Evolut FX+ valves, and renal denervation. The strategic separation of the capital-intensive MiniMed diabetes unit retires approximately 4% to 5% of outstanding equity while structurally eliminating margin-dilutive overhead. Crucially, trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry of $6.13 billion establishes a 5.2% cash yield that fully underwrites progressive dividend commitments and internal R&D. Valuation sensitivity remains acutely anchored to the sovereign macro backdrop. With benchmark 10-year Treasury yields near 5%, equity discount rates harshly penalize long-duration cash flows, preventing a return to historical peak multiples above 25 times earnings. Furthermore, aggressive commercial counterattacks from incumbent peers will inevitably erode electrophysiology catheter pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. Consequently, shareholder value must be generated primarily through earnings compounding, operational leverage from manufacturing footprint consolidation, and share retirement rather than speculative multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry.
Key insights
- Pulsed field ablation shifts electrophysiology revenue from cyclical equipment sales to high-margin recurring catheter pull-through, systematically expanding cardiovascular gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry.
- MiniMed's tax-free split-off functions as a discounted share repurchase, permanently lifting per-share intrinsic owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry without deploying liquid balance-sheet reserves.
- Restrictive sovereign borrowing costs constrain hospital capital budgets, enforcing flexible robotic leasing models and shifting economic returns onto single-use consumables.
Medtronic is moving past years of sluggish growth into a reliable earnings turnaround. Demand for essential medical treatments like heart valve replacements and cardiac ablation remains strong because older patients cannot delay vital surgeries. By spinning off its slower-moving diabetes business and shrinking its share count, Medtronic is streamlining operations. Generating over $6 billion in annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, the company easily protects its dependable 3% dividend payout while steadily compounding shareholder value.
Key insights
- High-tech heart ablation catheters generate steady, highly profitable repeat sales as hospitals replace older surgical tools.
- Separating the lower-margin diabetes division permanently reduces share count and immediately improves company-wide profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry.
- High interest rates limit expensive hospital equipment purchases, making performance dependent on everyday surgical consumable usage.
Deep Dive
Prevailing market consensus treats the enterprise as a lumbering, low-beta dividend utility trapped in historical 3% to 4% organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry. Investors anchor on past execution slips, hospital capital equipment freezes, and headline calendar distortions, viewing recent revenue acceleration as a transitory artifact. Consequently, the crowd prices the business at an undemanding multiple, heavily discounting management's margin turnaround narrative and treating competitive share erosion as permanent.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats the enterprise as a lumbering, low-beta dividend utility trapped in historical 3% to 4% organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry. Investors anchor on past execution slips, hospital capital equipment freezes, and headline calendar distortions, viewing recent revenue acceleration as a transitory artifact. Consequently, the crowd prices the business at an undemanding multiple, heavily discounting management's margin turnaround narrative and treating competitive share erosion as permanent.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value due to an analytical blind spot regarding underlying operational momentum. Consensus mistakenly dismisses Q1 fiscal 2027 performance as mere calendar noise, overlooking that organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry reached 7% led by an 88% surge in cardiac ablation. Furthermore, the market fails to price the EPS accretioneps accretionAn increase in earnings per share caused by a transaction, financing decision, operating change, or reduction in share count.View full glossary entry of retiring 4% to 5% of parent equity via the MiniMed split-off. This disconnect offers an attractive margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry anchored by a 5.2% free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? Completion of the MiniMed share exchange offer in late 2026, followed by consecutive ordinary-length quarterly prints confirming sustained 6.5%+ organic top-line growth, will close the gap. As reported operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry approach 19% without diabetes dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry, sell-side analysts will be forced to lift forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry estimates throughout fiscal 2027 and 2028, compelling institutional rotation into the shares.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment reflects tension between deep skepticism regarding historical conglomerate bureaucracy and growing institutional recognition of operational acceleration. Disagreement centers on whether high interest rates permanently cap equity multiples or merely delay an aggressive multiple re-rating.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop represents a mixed setup. Benchmark 10-year Treasury yields near 5% and restrictive central bank policy impose duration-driven multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and lengthen hospital capital equipment sales cycles. However, non-discretionary clinical procedural demand exhibits near-total economic inelasticity, insulating surgical implant volumes, cash collection, and debt service from consumer slowdowns.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement across reports centers on terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples and operational execution speed. Growth-oriented views argue that pipeline breakthroughs in pulsed field ablation and robotics justify aggressive multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry toward 20 to 24 times earnings. Conversely, skeptical frameworks insist that 5% benchmark bond yields, hospital capital freezes, and bureaucratic inertia will cap multiples near 15 to 16 times, limiting appreciation strictly to organic cash flow compounding. Resolving this tension requires tracking ordinary-length quarterly organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry without calendar distortions and monitoring electrophysiology gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry against competitive pricing pressure.
Base-Case Forces
Event Risk ScoreVery Low3/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Pulsed field ablation portfolio scale | Innovation And Product | +20% | +22% | Commercial adoption of the Affera mapping system and PulseSelect catheter is transforming electrophysiology, delivering 88% growth in cardiac ablation. This technology converts installations into recurring, high-margin consumable catheter revenue. Installed-base expansion captures procedure share from thermal ablation, driving sustained cardiovascular margin accretion and lifting earnings over the five-year forecast horizon. |
| Inelastic demographic surgical demand | Sector And Industry | +14% | +14% | Aging global demographics generate non-discretionary procedural volume for transcatheter aortic valves, leadless pacemakers, and neurostimulation devices. Non-deferrable chronic disease interventions insulate Medtronic from cyclical economic downturns. This biological volume momentum underpins reliable mid-single-digit organic top-line expansion and defensive operational cash generation exceeding $6 billion annually. |
| MiniMed split-off per-share accretion | Capital Allocation | +13% | +10% | Separating the capital-intensive diabetes unit via an equity exchange offer retires an estimated 4% to 5% of outstanding parent shares at a discount. This portfolio pruning eliminates margin-dilutive hardware manufacturing, reduces dividend payout liabilities, and sharpens return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry, immediately lifting structural earnings per share. |
| Manufacturing rationalization and operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry | Operational Efficiency | +11% | +14% | Aggressive supply-chain consolidation, plant footprint rationalization, and automated cleanroom manufacturing are reversing post-pandemic cost bloat. Operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry stabilized at 17.8% and possess a viable path toward 20% as commercial launches mature. Cost absorption allows incremental revenue to flow directly into expanding free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry per share. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Restrictive sovereign yield multiple ceiling | Macroeconomic And Macrofinancial | -9.0% | -4.0% | Benchmark 10-year Treasury yields hovering near 5% and central bank policy rates around 4% exert relentless downward gravity on equity valuation multiples. High risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry make Medtronic's 3% dividend yielddividend yieldA financial ratio showing how much a company pays out in dividends each year relative to stock price.View full glossary entry and 5.2% cash yield relatively less compelling, strictly capping multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and forcing total returns to rely entirely on earnings growth. |
| Hospital capital budget tightening headwinds | Macroeconomic And Macrofinancial | -8.0% | -7.0% | Elevated borrowing costs and tight healthcare operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry force hospital procurement committees to ration capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry. Healthcare networks defer large purchases of Hugo surgical robotic towers and advanced imaging consoles. This institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry rationing lengthens sales cycles, compressing upfront capital equipment revenue and slowing high-margin instrument utilization. |
| Intense electrophysiology competitive pricing warfare | Competitive Positioning | -7.0% | -8.0% | Well-capitalized peers, notably Boston Scientific and Abbott, are defending cath-lab market share through aggressive pricing and bundled contracts. As pulsed field ablation catheters proliferate, hospital purchasing consortiums demand deeper discounts. This rivalry forces elevated marketing expenses, compressing catheter average selling prices and limiting incremental gross profit expansion. |
| Global procurement price compression | Regulatory | -7.0% | -8.0% | Expanding centralized volume-based procurement across China and mandatory budgetary reimbursement caps in European single-payer systems enforce statutory price cuts on mature devices. These administrative price reductions inflict steady headwinds on mature cardiac pacing and spinal hardware lines, offsetting premium pricing gains achieved in advanced therapeutic categories. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Flagship implant Class I safety recall | 21% | -22% | A systemic hardware defect, dielectric breakdown, or battery failure across core pulsed field ablation or leadless pacemaker lines triggering an FDA Class I recall would be devastating. Beyond remediation expenses exceeding $1 billion, procedural halts and clinician defections to rival platforms would permanently impair cardiovascular earnings power. |
| Sovereign healthcare mandatory payment reset | 24% | -17% | Severe fiscal deficits forcing US legislative expansion of mandatory reimbursement price cuts across inpatient physician-preference implantable devices would crush hospital economics. Forcing statutory discounts on pacemakers, valves, and neuromodulation hardware would compress gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry below 60%, precipitating earnings contractions and multiple de-rating across medtech. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Renal denervation reimbursement floodgate opening | 34% | +21% | CMS establishing broad, permanent outpatient reimbursement alongside synchronized private payer coverage for Symplicity Spyral by 2028 would unlock a multi-billion-dollar market. Treating millions of uncontrolled hypertensive patients would accelerate corporate organic revenue growth above 8%, generating high-margin catheter cash flows and driving multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Hugo robotic multi-specialty FDA clearance | 29% | +18% | Securing unencumbered FDA 510(k) clearances for the Hugo robotic system in high-volume general surgery and gynecology before 2028 would break Intuitive Surgical's near-monopoly. Capturing substantial soft-tissue procedure volume would drive high-margin recurring instrument and stapler pull-through, lifting operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry beyond 21% and boosting valuation. |
Company Financial Analysis
Medtronic Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Medtronic's financial results demonstrate an unmistakable shift from multi-year stagnation toward authentic operational acceleration. For fiscal 2026, reported revenue expanded 8.4% to $36.4 billion, and the momentum continued into the first quarter of fiscal 2027 with reported organic growth of 13.7%. While an extra selling week flattered that headline figure, underlying growth remained solid at roughly 7%, spearheaded by an extraordinary 88% surge in cardiac ablation solutions. Crucially, this top-line resurgence is backed by genuine cash generation rather than accounting gimmicks. Trailing free cash flow reached $6.13 billion, comfortably funding $3.64 billion in annual dividend payments while supporting disciplined share buybacks. As high-margin procedural consumables outpace capital equipment sales, earnings quality is steadily improving across core divisions.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | USD 36.4B | USD 4.8B | USD 5.4B |
| 2025 | USD 33.5B | USD 4.7B | USD 5.2B |
| 2024 | USD 32.4B | USD 3.7B | USD 5.2B |
| 2023 | USD 31.2B | USD 3.8B | USD 4.6B |
| 2022 | USD 31.7B | USD 5B | USD 6B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2026 | 21.7x | TTM | Native | USD / USD |
| 2025 | 23.4x | TTM | Native | USD / USD |
| 2024 | 28.1x | TTM | Native | USD / USD |
| 2023 | 32.2x | Annual | Native | USD / USD |
| 2022 | 27.6x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability margins are establishing a durable floor after absorbing years of post-pandemic supply-chain inflation and tariff expenses. Gross margin held steady at 65.0% in fiscal 2026, while operating margin improved to 17.8%. In the first quarter of fiscal 2027, net income jumped 41% as manufacturing efficiencies and favorable procedural mix took hold. This margin recovery reflects structural improvements rather than temporary cost-cutting. Premium pulsed field ablation catheters command higher profitability than older thermal tools, while shedding the lower-margin diabetes division will immediately lift consolidated margins. As automated factory production expands, operating margins possess a clear pathway toward 20% over the next several years.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2026 | USD 6.5B | 17.8% | 13.2% |
| 2025 | USD 6B | 17.8% | 13.9% |
| 2024 | USD 5.1B | 15.9% | 11.4% |
| 2023 | USD 5.5B | 17.6% | 12.0% |
| 2022 | USD 5.8B | 18.2% | 15.9% |
Balance sheet and leverage
AI Review
Medtronic operates from a conservative financial position designed to navigate restrictive interest rate environments smoothly. The company closed fiscal 2026 with $93.0 billion in total assets against $49.5 billion in shareholder equity, resulting in a prudent debt-to-equity ratio of 0.57. Manageable debt servicing is underscored by an interest coverage ratio of 9.6 times. While gross debt stands near $28 billion and historical acquisitions leave substantial intangible assets on the books, robust operating liquidity and a current ratio of 2.13 provide substantial protection. Generating over $6 billion in annual free cash flow ensures Medtronic can easily service its obligations and sustain dividend increases without needing external borrowing.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2026 | USD 28B | USD 9.2B | USD 26B net debt | 2.13x |
| 2025 | USD 28.5B | USD 9B | USD 26.3B net debt | 1.85x |
| 2024 | USD 25B | USD 8B | USD 23.7B net debt | 2.03x |
| 2023 | USD 24.4B | USD 8B | USD 22.8B net debt | 2.39x |
| 2022 | USD 24.1B | USD 10.6B | USD 20.4B net debt | 1.86x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management is exercising tight capital discipline, maintaining capital expenditures at a modest 5.2% of revenue while directing $2.87 billion annually into targeted research and development. Rather than chasing expensive, dilutive mega-acquisitions, capital is deliberately focused on automated cleanrooms, precision tooling, and clinical regulatory trials for high-margin catheters and robotics. The most decisive capital allocation move is subtractive: spinning off the capital-intensive diabetes unit. Exiting pump manufacturing eliminates a business with high research requirements, freeing up financial resources for cardiac ablation and soft-tissue surgery. This selective reinvestment posture optimizes returns on invested capital and preserves strong cash conversion.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2026 | USD 1.9B | USD 2.9B |
| 2025 | USD 1.9B | USD 2.7B |
| 2024 | USD 1.6B | USD 2.7B |
| 2023 | USD 1.5B | USD 2.7B |
| 2022 | USD 1.4B | USD 2.7B |
Quarterly Forecast Scenarios
Medtronic Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $90.29 | $94.63 | $96.74 | $750.26 | |
| $93.90 | $97.27 | $100.61 | $736.44 | |
| $93.89 | $100.34 | $106.64 | $743.40 | |
| $95.84 | $102.63 | $109.84 | $755.15 | |
| $97.76 | $105.65 | $114.24 | $776.22 | |
| $98.74 | $107.55 | $116.52 | $787.13 | |
| $101.70 | $111.18 | $122.35 | $802.83 | |
| $101.70 | $113.43 | $126.02 | $812.05 | |
| $103.73 | $116.36 | $131.06 | $839.18 | |
| $101.66 | $118.66 | $133.68 | $850.50 | |
| $103.69 | $121.87 | $140.36 | $872.39 | |
| $104.73 | $124.27 | $144.57 | $885.51 | |
| $106.82 | $127.65 | $148.91 | $909.56 | |
| $106.82 | $129.87 | $151.89 | $916.13 | |
| $108.96 | $133.39 | $157.96 | $936.51 | |
| $110.05 | $135.89 | $162.70 | $947.34 | |
| $111.15 | $139.15 | $167.58 | $969.59 | |
| $111.15 | $141.39 | $170.94 | $979.99 | |
| $113.37 | $145.10 | $177.77 | $999.60 | |
| $114.51 | $147.87 | $183.11 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported consensus reveals an operational inflection in underlying organic revenue growth toward 6% to 7%, led by rapid pulsed field ablation adoption and resilient non-cyclical procedural demand. Multiple reports correlate by projecting substantial valuation re-rating; however, rigorous scrutiny proves multiple expansion is severely constrained by benchmark sovereign bond yields hovering near 5% and persistent tariff frictions. Heaviest weighting is awarded to analyses grounded in primary SEC filings, which correctly adjust Q1 fiscal 2027 performance for the 53-week calendar effect and model the MiniMed split-off as a share-count retirement rather than free cash infusion. Credible contrarian reasoning identifying hospital capital budget rationing, slow surgical robotics adoption, and inevitable electrophysiology catheter price erosion is preserved to counterbalance aggressive growth forecasts. Unsupported claims of dramatic multiple expansion toward historical zero-rate peaks are downweighted, grounding the consensus in cash-flow compounding and margin recovery.
Universal Investor AI
The Polymath
Opus 5Exemplary primary evidentiary grounding across regulatory filings and exchange offer mechanics. It correctly deconsolidates diabetes revenue, isolates the 53-week calendar effect, and rigorously articulates how tariff friction and sovereign yields cap multiple expansion while earnings compound.
Universal Investor AI
The Polymath
GPT-6 AstraThis analysis provides rigorous primary source verification across SEC filings and clinical notices. It properly adjusts reported Q1 growth for the extra selling week and treats MiniMed separation economics realistically. Its valuation cross-check against benchmark bond yields anchors prudent baseline compounding.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashPresents strong macroeconomic causal framing contrasting late-cycle sovereign debt yields with inelastic procedural demand. The rationale incisively details per-share accretion from the MiniMed exchange offer, though it slightly downplays persistent competitive pricing pushback in electrophysiology.
Elon Musk AI
The Visionary
Gemini 3.8 FlashDelivers an essential contrarian critique highlighting corporate bureaucratic inertia, surgical robotics commercialization lag, and hospital capex impasses. While its organic growth forecast of 5.5% is excessively punitive, its skepticism on multiple expansion provides a vital ballast.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashSound long-term owner orientation focused on durable procedural moats and free cash flow generation. However, it lacks primary research source citations and models multiple expansion too optimistically despite acknowledging hospital capital budget rationing headwinds.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashOffers solid reasoning regarding supply-chain rationalization and manufacturing leverage. Nevertheless, it accepts headline revenue acceleration without adjusting for calendar distortions and unconvincingly assumes multiple re-rating to 25 times earnings in a restrictive interest rate environment.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAccurately maps the clinical reimbursement opportunity for renal denervation alongside solid balance sheet metrics. It lacks specific SEC source citations and treats the diabetes separation merely as an upside tail option rather than an ongoing corporate action.
Michael Burry AI
The Vulture
Gemini 3.8 FlashProvides sharp forensic insights into plant rationalization, footprint exits, and activist governance influence on margins. It models steep multiple re-rating without thoroughly accounting for electrophysiology catheter average selling price erosion from competing platforms.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashAccurately normalizes Q1 organic top-line velocity and highlights capital-light console placement dynamics. However, it relies heavily on unmodeled forward multiple re-rating and overlooks transition service liabilities following the diabetes unit separation.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashStrong analysis of institutional coding durability and regulatory capture via CMS renal denervation determinations. However, it assumes an aggressive multiple re-rating to 20 times forward earnings that conflicts with broader sovereign yield pressures.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashAccurately identifies non-cyclical biological procedural demand as a shield against macroeconomic stagflation. It overstates diabetes hardware retention benefits by failing to recognize the near-term completion of the MiniMed split-off exchange offer.
Universal Investor AI
The Polymath
Gemini 3.8 FlashGood synthesis of fixed-cost operational leverage and structural heart franchise stability. Yet it misses the specific structural mechanics of the share retirement in the pending split-off, treating portfolio separation more loosely than primary documentation warrants.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashPresents an aggressive growth thesis emphasizing hospital procurement lock-in. However, the path relies on heroic multiple expansion to 19 times and doubling enterprise value, largely dismissing serious competitive counter-offensives and ongoing product liability litigation risks.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashConstructs an insightful narrative around clinical software integration into cath-lab hardware. However, the projected 98% five-year equity price trajectory is fundamentally disconnected from disciplined cash-flow discounting in an elevated sovereign yield regime.
Research Provenance
References & Context
This Medtronic consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 37 deduplicated sources retained for this batch.
- 01Renal Denervation for Uncontrolled Hypertension | CMScms.gov
- 02Documentsec.gov
- 03mdt-20260424sec.gov
- 04Medtronic plc - Form 10-Q - FY2026sec.gov
- 05Medtronic plc - Form 8-K - FY2026sec.gov
- 06Medtronic plc - Form 8-K - FY2026sec.gov
- 07www.sec.govsec.gov
- 08https://assets.hpra.ie/data/docs/default-source/product-updates/fsn/field-safety-notices/march-2026/sphere-9-catheter_medtronic-inc-_advice-regarding-changes-or-updates-made-to-instructions-for-use.pdf?sfvrsn=e2ba80ec_3assets.hpra.ie
- 09Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - BioSpacebiospace.com
- 10Medtronic Diabetes to submit patch pump to FDA by fall 2026drugdeliverybusiness.com
- 11Medtronic PLC (MDT) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and Raised ...finance.yahoo.com
- 12Medtronic launches exchange offer to split off MiniMed stake - Financial Newsfinancial-news.co.uk
- 13Medtronic (MDT) to Announce Q1 FY2027 Earnings on August 18gurufocus.com
- 14Medtronic Diabetes Business Separation - iData Researchidataresearch.com
- 15Earnings call transcript: Medtronic beats Q1 2026 estimates and lifts outlook By Investing.cominvesting.com
And 22 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2015-04-30–2026-04-30, 12 periods; quarterly: 2023-10-31–2026-07-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.